바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

572누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

ADCBiologicstaleShanghai JMT-Bio Inc.Phase 3

JSKN003 (JSKN003)

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 11상태 RECRUITING

ADCBiologicstaleSWOG Cancer Research NetworkPhase 2

ABBV-399 (ABBV-399)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC V7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 33.3%임상시험 11상태 ACTIVE

ADCBiologicstaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 56.5%임상시험 11상태 RECRUITING

CGTBiologicKyverna TherapeuticsPhase 2

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 11상태 RECRUITING

ADCBiologicstalePfizerPhase 2

PF-08634404 (PF-08634404)

Urothelial Cancer; Advanced/Metastatic Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 11상태 RECRUITING

CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오모아추천+5

효능 ORR 55%임상시험 10상태 APPROVED

CGTBiologicstaleNovartisPhase 1

huCART19 (huCART19)

Acute Lymphocytic Leukemia; Diffuse Large Cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 10상태 ACTIVE

CGTBiologicTakedaPhase 2

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Hematologic Malignancies · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3

효능 ORR 20%임상시험 10상태 RECRUITING

AntibodystaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+3

임상시험 10상태 RECRUITING

ADCBiologicstaleCuris, Inc.Phase 1

Emavusertib (Emavusertib)

Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

임상시험 10상태 RECRUITING

ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 10상태 ACTIVE

CGTBiologicstaleImmunityBio, Inc.Phase 1

super NK cell (super NK cell)

AML, Adult; Minimal Residual Disease · AML, Adult

#AMLAdult#CGT#Phase1#세포유전치료#CAR-T+5

효능 ORR 0%임상시험 10상태 ACTIVE

ADCBiologicstaleGenentech, Inc.Phase 2

Taselisib (Taselisib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 50%임상시험 10상태 ACTIVE

CGTBiologicstaleChongqing University Cancer Hos…Phase 2

Oncolytic Virus H101 (Oncolytic Virus H101)

Rectal Neoplasms; Rectal Adenocarcinoma · Rectal Neoplasms

#RectalNeoplasms#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 10상태 RECRUITING

CGTBiologicstaleAsclepius Technology Company Gr…Phase 1

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

Multiple Myeloma, Refractory · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 10상태 ACTIVE

CGTBiologicNational Heart, Lung, and Blood…vedotinPhase 1

AVL (AAV8hAAT, AAV8hAAT(AVL))

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 10상태 RECRUITING

AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Injection [Keytruda])

Gestational Trophoblastic Neoplasia · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+3

임상시험 10상태 ACTIVE

ADCBiologicstaleHoffmann-La RochePhase 2

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 10상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

효능 ORR 1.4%임상시험 10상태 DISCONTINUED

AntibodystaleEli LillyPhase 1

Cetuximab-IRDye800 (Cetuximab-IRDye800)

Drug Safety ; Drug Specificity · Glioblastoma

#Glioblastoma#Antibody#Phase1#항체#면역항체+4

임상시험 10상태 ACTIVE

AntibodystaleSanofiPreclinical

Dupilumab - Standard Dose (Dupilumab - Standard Dose)

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP); Smell Loss · Atopic Dermatitis

#AtopicDermatitis#Antibody#Preclinical#항체#면역항체+4

임상시험 10상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 3

R-mini-CHOP (R-mini-CHOP)

Large B-cell Lymphoma · DLBCL

#DLBCL#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 94.1%임상시험 10상태 RECRUITING

ADCBiologicstaleAstellas Pharma IncPhase 1

AGS-22M6E (AGS-22M6E)

Tumors; Medical Oncology · Tumors

#Tumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 10상태 ACTIVE

CGTBiologicstaleShenzhen Celconta Life Science …Phase 1

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 10상태 RECRUITING

CGTBiologicMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma · B-Cell Neoplasm

#B-CellNeoplasm#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 10상태 RECRUITING

37 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 572

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

JSKN003 (JSKN003)

ABBV-399 (ABBV-399)

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

PF-08634404 (PF-08634404)

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

huCART19 (huCART19)

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Cevostamab (Cevostamab)

Emavusertib (Emavusertib)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

super NK cell (super NK cell)

Taselisib (Taselisib)

Oncolytic Virus H101 (Oncolytic Virus H101)

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

AVL (AAV8hAAT, AAV8hAAT(AVL))

pembrolizumab (Keytruda, Pembrolizumab Injection [Keytruda])

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Zilovertamab vedotin (Zilovertamab vedotin)

Cetuximab-IRDye800 (Cetuximab-IRDye800)

Dupilumab - Standard Dose (Dupilumab - Standard Dose)

R-mini-CHOP (R-mini-CHOP)

AGS-22M6E (AGS-22M6E)

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

JSKN003 (JSKN003)

ABBV-399 (ABBV-399)

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

PF-08634404 (PF-08634404)

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

huCART19 (huCART19)

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Cevostamab (Cevostamab)

Emavusertib (Emavusertib)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

super NK cell (super NK cell)

Taselisib (Taselisib)

Oncolytic Virus H101 (Oncolytic Virus H101)

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

AVL (AAV8hAAT, AAV8hAAT(AVL))

pembrolizumab (Keytruda, Pembrolizumab Injection [Keytruda])

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Zilovertamab vedotin (Zilovertamab vedotin)

Cetuximab-IRDye800 (Cetuximab-IRDye800)

Dupilumab - Standard Dose (Dupilumab - Standard Dose)

R-mini-CHOP (R-mini-CHOP)

AGS-22M6E (AGS-22M6E)

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

JSKN003 (JSKN003)

ABBV-399 (ABBV-399)

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

PF-08634404 (PF-08634404)

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

huCART19 (huCART19)

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Cevostamab (Cevostamab)

Emavusertib (Emavusertib)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

super NK cell (super NK cell)

Taselisib (Taselisib)

Oncolytic Virus H101 (Oncolytic Virus H101)

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

AVL (AAV8hAAT, AAV8hAAT(AVL))